Drugs by condition
Drugs approved for eosinophilic esophagitis
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
2
Still marketed, NDA or BLA
Drug classes
2
Novel drugs
1
New molecular entities and new biologics
In development
6
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for eosinophilic esophagitis.
All approved drugs for eosinophilic esophagitis, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Drugs in development for eosinophilic esophagitis
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- cendakimabCC-93538, BMS-986355Phase 31 trial
Bristol Myers Squibb · Eosinophilic Esophagitis
- SolrikitugPhase 22 trials
Uniquity One (UNI) · Eosinophilic Esophagitis (EoE), COPD
- EP-104GIPhase 21 trial
Eupraxia Pharmaceuticals Inc. · Eosinophilic Esophagitis
- NDX-3315Phase 21 trial
NexEos Diagnostics, Inc. · Eosinophilic Esophagitis
- NDX-3324Phase 21 trial
NexEos Diagnostics, Inc. · Eosinophilic Esophagitis
More on eosinophilic esophagitis: recruiting trials · published research
Related in gastroenterology and liver: MASH (fatty liver disease) · Primary biliary cholangitis · Acid reflux (GERD) · Irritable bowel syndrome · Chronic constipation · Nausea and vomiting
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.